Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- MDA Engage: Patients can take steps to improve breathing issues
- Low muscle mass may help predict survival in people with ALS
- The changing of the seasons reminds me of life with ALS
- Targeted therapy may improve function, survival in FUS-ALS
- Building small habits through exercise to stay strong with ALS